Crown Bioscience published recent data from models showcasing distinct approaches to therapeutic resistance in lung cancer, including engineering patient-derived organoids with TROP2 knockout and evaluating resistance in pretreated NSCLC PDX and organoid systems.

Crown Bioscience is a global contract research organization (CRO) dedicated to accelerating drug discovery and development in oncology and immuno-oncology. We partner with biotech and pharmaceutical companies to deliver integrated preclinical and translational research solutions, supporting programs from target discovery through clinical development. Our portfolio includes more than 2,800 patient-derived xenograft (PDX) models and approximately 1,000 tumor organoid models across 35 cancer indications, supported by expertise in in vivo, in vitro, ex vivo, and in silico research. Combined with advanced laboratory services, multiomics capabilities, and data science, we help generate the insights needed to support confident decision-making throughout the drug development continuum. Operating from 9 facilities across the US, Europe, and APAC, our laboratories meet the highest industry standards and include CAP-, CLIA-, and ISO 15189-accredited facilities. To learn more, visit www.crownbio.com